Burnaby, British Columbia – February 10, 2025 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel […]
Read More >
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
Burnaby, British Columbia – January 6, 2025 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
Burnaby, British Columbia – December 16, 2024 – Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators […]
Read More >
Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
Vancouver, BC – June 7, 2024 – Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that […]
Read More >
Qu Biologics and Foundation Medicine Collaborate to Impact the Care of Patients with Late-Stage Colorectal Cancer
Burnaby, British Columbia — June 06, 2024 — Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), […]
Read More >